Erlotinib for Hepatocellular Carcinoma Chemoprevention

Part of paid clinical trials in Dallas, Texas.

Sponsor
University of Texas Southwestern Medical Center
Study ID
NCT04172779
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Advanced Liver Fibrosis
  • Cirrhosis, Liver

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This phase II randomized placebo-controlled trial studies low-dose erlotinib treatment to assess its efficacy and safety to prevent development of hepatocellular carcinoma in patients with advanced liver fibrosis or cirrhosis.

Key Dates

Start date
Aug 31, 2026
Status verified
Apr 2026
Primary completion
Dec 31, 2030
Completion
Dec 31, 2030

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION

Arms

  • Experimental: Erlotinib treatment
  • Placebo Comparator: Placebo

Primary Outcome Measure

Modulation of serum protein signature associated with hepatocellular carcinoma (HCC) risk [ Time Frame: Baseline, 24 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
UT Southwestern Medical CenterDallasTexas75390
Yujin Hoshida
[email protected]
2146486137

Find similar trials in Dallas, TX

By research site
UT Southwestern Medical Center· Dallas, TX

Related Studies